Article Text

other Versions

PDF
Letter
The impact of preoperative biological therapy on complications after abdominal surgery for inflammatory bowel disease
  1. Takayuki Yamamoto,
  2. Manabu Shiraki
  1. Inflammatory Bowel Disease Centre, Yokkaichi Social Insurance Hospital, Yokkaichi, Mie, Japan
  1. Correspondence to Dr Takayuki Yamamoto, Inflammatory Bowel Disease Centre, Yokkaichi Social Insurance Hospital, 10-8 Hazuyamacho, Yokkaichi, Mie 510-0016, Japan; nao-taka{at}sannet.ne.jp

Statistics from Altmetric.com

We read with interest the article by Waterman et al,1 ‘Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease (IBD)’. The authors had conducted a retrospective study evaluating the impact of preoperative biological therapy on complications after surgery for IBD. Preoperative treatment with tumour necrosis factor-α antagonists was not associated with postoperative infectious complications, anastomotic leaks and other perioperative complications. Based on these results, they do not recommend altering antitumour necrosis factor therapy, or the scheduling of surgery to prolong the time interval to operation.

We agree with the authors' recommendation. Surgery should not be delayed, and appropriate biological therapy should be continued perioperatively. However, surgeons would like to …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.